Genetic evolution of influenza viruses among selected countries in Latin America, 2017-2018.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
06
2019
accepted:
03
01
2020
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
28
5
2020
Statut:
epublish
Résumé
Since the 2009 influenza pandemic, Latin American (LA) countries have strengthened their influenza surveillance systems. We analyzed influenza genetic sequence data from the 2017 through 2018 Southern Hemisphere (SH) influenza season from selected LA countries, to map the availability of influenza genetic sequence data from, and to describe, the 2017 through 2018 SH influenza seasons in LA. We analyzed influenza A/H1pdm09, A/H3, B/Victoria and B/Yamagata hemagglutinin sequences from clinical samples from 12 National Influenza Centers (NICs) in ten countries (Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, Paraguay, Peru and Uruguay) with a collection date from epidemiologic week (EW) 18, 2017 through EW 43, 2018. These sequences were generated by the NIC or the WHO Collaborating Center (CC) at the U.S Centers for Disease Control and Prevention, uploaded to the Global Initiative on Sharing All Influenza Data (GISAID) platform, and used for phylogenetic reconstruction. Influenza hemagglutinin sequences from the participating countries (A/H1pdm09 n = 326, A/H3 n = 636, B n = 433) were highly concordant with the genetic groups of the influenza vaccine-recommended viruses for influenza A/H1pdm09 and influenza B. For influenza A/H3, the concordance was variable. Considering the constant evolution of influenza viruses, high-quality surveillance data-specifically genetic sequence data, are important to allow public health decision makers to make informed decisions about prevention and control strategies, such as influenza vaccine composition. Countries that conduct influenza genetic sequencing for surveillance in LA should continue to work with the WHO CCs to produce high-quality genetic sequence data and upload those sequences to open-access databases.
Identifiants
pubmed: 32155152
doi: 10.1371/journal.pone.0227962
pii: PONE-D-19-16505
pmc: PMC7064222
doi:
Substances chimiques
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0227962Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Vaccine. 2016 Sep 22;34(41):4905-4912
pubmed: 27577556
Nat Rev Microbiol. 2018 Jan;16(1):47-60
pubmed: 29081496
Vaccine. 2018 Jun 7;36(24):3555-3566
pubmed: 28648543
J Infect Dis. 2014 Jul 1;210(1):126-37
pubmed: 24446529
PLoS Pathog. 2017 Dec 28;13(12):e1006749
pubmed: 29284042
Pharmacoeconomics. 2018 Dec;36(12):1475-1490
pubmed: 30251078
Influenza Other Respir Viruses. 2016 May;10(3):170-5
pubmed: 26701079
Nature. 2015 Jul 9;523(7559):217-20
pubmed: 26053121
Med Ref Serv Q. 2019 Oct-Dec;38(4):358-368
pubmed: 31687905